29Aug 2023
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in HFmrEF/HFpEF

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in HFmrEF/HFpEF

A study revealed that COPD is prevalent among heart failure patients with mildly reduced or preserved ejection fractions (HFmrEF/HFpEF) and is linked to poorer outcomes. They found that patients with mild-to-moderate COPD faced a higher risk of cardiovascular death or worsening HF. However, the diabetes drug dapagliflozin showed consistent benefits in reducing these risks across all COPD statuses. This suggests dapagliflozin could be a valuable addition to HFmrEF/HFpEF treatment, regardless of COPD presence.

  • #cardiology

Like

Save

Share